- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
HumaScan delays BreastAlert launch
Developmental-stage company HumaScan has hit a roadblock in its quest to commercialize a nonimaging screening device for breast cancer that could compete with mammography. The company anticipates a four to six-month delay for its BreastAlert Differential
Developmental-stage company HumaScan has hit a roadblock in its quest to commercialize a nonimaging screening device for breast cancer that could compete with mammography. The company anticipates a four to six-month delay for its BreastAlert Differential Temperature Sensor (DTS), a noninvasive, adjunctive screening device for breast disease.
BreastAlert DTS detects temperature differences between breasts, which may indicate the presence of breast disease, including breast cancer, according to the Cranford, NJ-based company.
The initial introduction of BreastAlert DTS was scheduled to begin in the New York metropolitan area on June 30, but was pushed back to make manufacturing refinements the company believes are necessary to achieve consistent, high-quality production. HumaScan anticipates proceeding with its planned national launch in the fourth quarter of 1997.
HumaScan has approximately $11 million in cash and equivalents on hand, and with monthly expenditures of about $325,000, the company believes that it has more than enough capital on hand to successfully launch BreastAlert DTS.
Medical supply company Physicians Sales and Service, which signed an exclusive supply and distribution agreement with HumaScan in February 1996, appears to be supporting HumaScan's decision to delay the launch of BreastAlert DTS. PSS chairman Patrick Kelly said that PSS remains committed to the exclusive distribution of BreastAlert DTS.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
